| Male / female; number (%) |
14 / 13 (52 / 48) |
| Age, years; median (range) |
59 (40-67) |
| Myeloma subtype, (%) |
|
| IgG |
26 |
| IgA |
26 |
| Light chain |
33 |
| Non secretory |
7 |
| Other |
7 |
| Durie-Salmon disease stage I / II / III, (%) |
22 / 19 / 59 |
| International Staging System disease stage I / II / III, (%) |
61 / 17 / 22 |
| β2-microglobulin, (mg/L); median (range) |
3 (1.6 - 44.5) |
| Hemoglobin, g/L; median (range) |
11 (5.5 - 15.4) |
| Creatinine, μmol/L; median (range) |
93 (45 - 336) |
| Calcium, mmol/L; median (range) |
2.5 (2.3 - 4.4) |
| Albumin, g/L; median (range) |
40 (30 - 53) |
| Plasma cells by morphology, % |
36 (10 - 72) |
| Malignant plasma cell phenotype, cases by 7-color flow cytometry, (%) |
|
| CD19− |
92 |
| CD20+ |
17 |
| CD27− |
67 |
| CD45− |
88 |
| CD56+ |
67 |
| CD117+ |
25 |
| CD200+ |
71 |
